Polymeric Carriers for Delivery of RNA Cancer Therapeutics

Author:

Mirón-Barroso Sofía1ORCID,Correia Joana2ORCID,Frampton Adam13ORCID,Lythgoe Mark1ORCID,Clark James1,Tookman Laura1,Ottaviani Silvia4ORCID,Castellano Leandro5ORCID,Porter Alexandra2,Georgiou Theoni2ORCID,Krell Jonathan1

Affiliation:

1. Department of Surgery and Cancer, Imperial College, London W12 0HS, UK

2. Department of Materials, Imperial College London, London SW7 2AZ, UK

3. Department of Clinical and Experimental Medicine, University of Surrey, Guildford GU2 7XH, UK

4. Department of Biosciences, Nottingham Trent University, Nottingham NG1 4FQ, UK

5. School of Life Sciences, University of Sussex, Brighton BN1 9RH, UK

Abstract

As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘druggable’ active binding sites. In recent decades, RNA therapeutics have gained popularity due to their ability to affect targets that small molecules cannot. Additionally, they can be manufactured more rapidly and cost-effectively than small molecules or recombinant proteins. RNA therapeutics can be synthesised chemically and altered quickly, which can enable a more personalised approach to cancer treatment. Even though a wide range of RNA therapeutics are being developed for various indications in the oncology setting, none has reached the clinic to date. One of the main reasons for this is attributed to the lack of safe and effective delivery systems for this type of therapeutic. This review focuses on current strategies to overcome these challenges and enable the clinical utility of these novel therapeutic agents in the cancer clinic.

Funder

Medical Research Council

Publisher

MDPI AG

Subject

Genetics,Molecular Biology,Biochemistry

Reference146 articles.

1. Cancer Statistics;Siegel;CA Cancer J. Clin.,2021

2. A view on drug resistance in cancer;Vasan;Nature,2019

3. Hallmarks of cancer: The next generation;Hanahan;Cell,2011

4. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia;Byrd;N. Engl. J. Med.,2013

5. The druggable genome;Hopkins;Nat. Rev. Drug Discov.,2002

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3